Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of Ifenprodil for COVID-19 infection

Trial Profile

Phase II trial of Ifenprodil for COVID-19 infection

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2020

At a glance

  • Drugs Ifenprodil (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Algernon Pharmaceuticals
  • Most Recent Events

    • 06 Apr 2020 New trial record
    • 02 Apr 2020 According to an Algernon Pharmaceuticals media release, the company is working to prepare all documentation for an ethics approval submission in Australia, which will be filed shortly.
    • 02 Apr 2020 According to an Algernon Pharmaceuticals media release, the decision to conduct this study is based on the results of a recently conducted successful feasibility study.

Trial Overview

Purpose

This trial will evaluate Ifenprodil for COVID-19 infection.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Sponsors Algernon Pharmaceuticals
  • Affiliations Algernon Pharmaceuticals

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase II
  • Location Australia
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
IfenprodilPrimary Drug Oral
-

Ifenprodil

Trial Centres

Centres

Centre Name Location Trial Centre Country
Algernon Pharmaceuticals
-
-

Trial History

Event Date Event Type Comment
06 Apr 2020 New trial record New trial record Updated 06 Apr 2020
02 Apr 2020 Other trial event According to an Algernon Pharmaceuticals media release, the company is working to prepare all documentation for an ethics approval submission in Australia, which will be filed shortly. Updated 14 Apr 2020
02 Apr 2020 Other trial event According to an Algernon Pharmaceuticals media release, the decision to conduct this study is based on the results of a recently conducted successful feasibility study. Updated 06 Apr 2020
02 Apr 2020 Other trial event According to an Algernon Pharmaceuticals media release, the company has retained Novotech to conduct this study. Updated 06 Apr 2020

References

  1. Algernon Pharmaceuticals. Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19. Media-Rel 2020;.

    Media Release
Back to top